Vyne Therapeutics rises as early-stage trial dosing of skin drug starts

YARROW BIOSCIENCE

10/01/2023 13:03

** Vyne Therapeutics Inc's  VYNE.O  shares rise 62% to $0.31
premarket
    ** Drug developer says first patient dosed in an early-stage
trial of experimental drug VYN201 for treatment of vitiligo, a
common chronic disorder characterized by depigmentation of the
skin
    ** Expects data from trial in H1 this year
    ** 3 of 4 brokerages rate the stock "buy", 1 "hold"; median
PT $4 - Refinitiv
    ** Vyne shares fell 85% in 2022
 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com; Twitter: https://twitter.com/LeroyLeo7))